ISSN: 0443-511
e-ISSN: 2448-5667
Herramientas del artículo
Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión)
Tamaño de fuente

Open Journal Systems

Clinical evaluation of diabetic neuropathy in adult patients with type 1 diabetes and its possible association with insulin resistance

Claudia González-Milán, Claudia Ramírez-Rentería, Mario Molina-Ayala, Aldo Ferreira-Hermosillo


Background: In Mexico, there is a lack of information regarding the prevalence and characteristics of Diabetic Neuropathy (DN) in patients with type 1 diabetes (T1D). Although it was, considered as a country with low-incidence of T1D, recent publications show that T1D frequency is under-represented. The aim of this paper is to describe the frequency and severity of DN in patients with T1D using a clinical scale and assess its possible association with insulin resistance.

Methods: We evaluated 48 patients from T1D Clinic. We assessed clinical and biochemical characteristics and determined insulin resistance through estimated glucose dispose rate (eGDR). Patients underwent a neurologic evaluation using a previously validated score.

Results: Seventy-three percent of patients had DN (54% mild and 19% moderate neuropathy). Twenty-nine percent of total population had Metabolic Syndrome. Major predictor factors for DN were the presence of diabetes for more than 13 years (OR 4.6, CI95%: 1.09-15.7), achieving treatment goals during the first 5 years (OR 0.22, CI95%: 0.05-0.87) and eGDR > 7.32 mg/kg/min (OR 0.096, CI95%: 0.011-0.81).

Conclusions: The clinical scale performed in this study is a useful screening tool for DN in adults with long-standing T1D. DN is more frequent in patients with longer evolution of diabetes and poor glucose control during the initial years after diagnosis as expected, but insulin resistance should also be considered as an additional risk factor in this group.

Palabras clave

Diabetes Mellitus, Type 1; Diabetic Neuropathies; Metabolic Syndrome

Texto completo:

PDF (English) PubMed


Vinik AI, Nevoret ML, Casellini C, Parson H: Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42:747-787.


Callaghan BC, Hur J, Feldman EL. Diabetic neuropathy: One disease or two? Curr Opin Neurol. 2012;25:536-541.


Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL: Diabetic neuropathy: Clinical manifestations and current treatments. Lancet Neurol. 2012;11:521-534.


Aliss-Samur JA, Ibarra-Olmos A, González-Barcena D. Prevalencia de neuropatía periférica en diabetes mellitus. Acta Médica Grupo Angeles. 2006;4:13-17.


Ferreira-Hermosillo A, Molina-Ayala M, Ramírez-Rentería C, Vargas G, González B, Isibasi A, et al. Inflammatory Cytokine Profile Associated with Metabolic Syndrome in Adult Patients with Type 1 Diabetes. J Diabetes Res. 2015;2015:972073.


Ferreira-Hermosillo A, Ramírez-Rentería C, Mendoza-Zubieta V, Molina-Ayala MA. Utility of the waist-to-height ratio, waist circumference and body mass index in the screening of metabolic syndrome in adult patients with type 1 diabetes mellitus. Diabetol Metab Syndr. 2014;6:32.


Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281-1289.


Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.


Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al: Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645.


Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes. 2000;49:626-632.


Akobeng AK. Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr. 2007;96:644-647.


Gillespie KM. Type 1 diabetes: Pathogenesis and prevention. CMAJ. 2006;175:165-170.


Jaiswal M, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, et al. Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: A pilot study. Diabetes Care. 2013;36:3903-3908.


Cleland SJ. Cardiovascular risk in double diabetes mellitus - When two worlds collide. Nat Rev Endocrinol. 2012;8:476-485.


Teupe B, Bergis K. Epidemiological evidence for “double diabetes”. Lancet. 1991;337:361-362.


Zhao W, Zeng H, Zhang X, Liu F, Pan J, Zhao J, et al. A high thyroid stimulating hormone level is associated with diabetic peripheral neuropathy in type 2 diabetes patients. Diabetes Res Clin Pract. 2016;115:12-9.


Chillaron JJ, Sales MP, Sagarra E, Castells I, Benaiges D, Flores Le-Roux JA, Pedro-Botet J. Chronic complications in type 1 diabetes mellitus. Analysis of a cohort of 291 patients with a mean evolution time of 15 years. Rev Clin Esp. 2012;212:375-382.


American Diabetes Association. Standards of Medical Care in Diabetes-2016 Abridged for Primary Care Providers. Clin Diabetes. 2016;34(1):3-21.


Berezin A. Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives. Diabetes Metab Syndr. 2016;10(Suppl 1)S176-83.


Barquera S, Campos-Nonato I, Hernández-Barrera L, Pedroza A, RiveraDommarco JA. Prevalence of obesity in Mexican adults 2000-2012. Salud Pública Mex. 2013;55(Suppl 2):S151-160.

Enlaces refback

  • No hay ningún enlace refback.